11C-methionine(11C-methionine) - 在研适应症：家族性室管膜瘤，横纹肌肉瘤，颅咽管瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用方式

增强剂

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症

家族性室管膜瘤横纹肌肉瘤颅咽管瘤

非在研适应症-

原研机构

St. Jude Children's Research Hospital, Inc.

在研机构

St. Jude Children's Research Hospital, Inc.

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

16

项与 11C-methionine 相关的临床试验

EUCTR2020-000640-64-CZ

/ Not yet recruiting临床2期IIT

11C-METHIONIN IN DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH AGGRESSIVE GLIOBLASTOM SHOWING A TIME POST-OPERATING PROGRESS BEFORE INITIATING ADJUVANT ONCOLOGICAL TREATMENT - GlioMET

开始日期2020-05-26

申办/合作机构-

NCT05608395

/ Active, not recruiting临床2期IIT

11C-methionine in Diagnostics and Management of Glioblastoma Multiforme With Rapid Early Progression Patients Prior to Adjuvant Oncological Therapy (GlioMET)

Glioblastoma multiforme (GBM) is the most common primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e. radiotherapy, chemotherapy, or combination of both at te same time. If post-operative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is planned. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery, i.e. rapid early progression (REP). Radiotherapy planning is based on this MRI in all patients. However, a subset of patients with REP have a less favorable prognosis with this treatment management. The investigators therefore assume that these patients need a more thorough examination to form a precise radiotherapy plan. The project focuses on this group of patients with a less favorable prognosis (with a more aggressive disease). Patients who develop REP within approximately 6 weeks after surgery will have PET/CT (positron emission tomography in combination with computed tomography) examinations using the radiopharmaceutical 11C-methionine in addition to standard practice. PET is one of the most modern methods of molecular imaging, a non-invasive in vivo method that allows physicians to study processes in the human body using radiolabeled radiopharmaceuticals. 11C-methionine is an example of a radiolabeled (carbon 11) amino acid - a source of energy for tumor cells and a building material for new proteins. This radiopharmaceutical is commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. For patients who undergo this examination, the radiotherapy planning will be adjusted based on it. The purpose of clinical trial is to improve the prospects of patients with REP.

开始日期2020-05-01

申办/合作机构

Masaryk Memorial Cancer Institute

JPRN-UMIN000037036

/ RecruitingN/AIIT

Study to investigate growth style of brain tumor using 11C-methionine PET - Study to investigate growth style of brain tumor using 11C-methionine PET

开始日期2019-06-12

申办/合作机构-

100 项与 11C-methionine 相关的临床结果

登录后查看更多信息

100 项与 11C-methionine 相关的转化医学

登录后查看更多信息

100 项与 11C-methionine 相关的专利（医药）

登录后查看更多信息

30

项与 11C-methionine 相关的文献（医药）

2024-06-01·Cancer biotherapy & radiopharmaceuticals

Evaluating the Diagnostic Efficacy of ^99mTc-Methionine Single-Photon Emission Computed Tomography–Computed Tomography: A Head-to-Head Comparison with ¹¹C-Methionine Positron Emission Tomography–Magnetic Resonance Imaging in Glioma Patients

Article

作者: Saini, Jitender ; Sitani, Keerti ; Sadashiva, Nishanth ; Beniwal, Manish ; Basavaraja, Harish ; Mishra, Anil Kumar ; Mangalore, Sandhya ; Rajan, Archith ; Nagaraj, Chandana ; Kumar, Aishwarya ; Santosh, Vani ; Kumar, Pardeep ; Hazari, Puja Panwar

Background: Amino acid positron emission tomography (PET) imaging plays a significant role in the diagnosis of gliomas and in differentiating tumor recurrence from necrosis. In this study, the authors evaluated the diagnostic efficacy of [^99mTc]Tc-methionine single-photon emission computed tomography-computed tomography (SPECT-CT) in comparison with [¹¹C]methionine PET-magnetic resonance imaging (MRI) in delineating tumors. Methods: Thirty-one (primary: 16 and postoperative: 15) patients of confirmed (either MRI or histopathological proven) glioma underwent both [^99mTc]Tc-methionine SPECT-CT and [¹¹C]methionine PET-MRI. A comparative analysis was performed between SPECT, PET, and MR images to calculate the concordance between the modalities and to evaluate the diagnostic efficacy of the [^99mTc]Tc-methionine SPECT. Results: [^99mTc]Tc-methionine SPECT showed comparable uptake in the tumor lesions in comparison to [¹¹C]methionine PET. A significant and strong positive correlation was observed between the volume of tumor (Vt) in PET and Vt MR (p < 0.004). Likewise, a significant and strong positive correlation was found between Vt SPECT and Vt MR. [^99mTc]-methionine has a sensitivity and specificity of 91% and 75%, respectively, compared with 82% and 100% for [¹¹C]methionine in postoperative cases to differentiate the tumor recurrence from necrosis. The sensitivity and specificity of [^99mTc]Tc-methionine was 92% and 100%, respectively, compared with 92% and 67% for [¹¹C]methionine in primary tumors. Conclusion: [^99mTc]Tc-methionine SPECT-CT is as equally good as [¹¹C]methionine for diagnosing and differentiating it from necrosis especially in high-grade glioma.

2023-08-01·Journal of neuro-oncology

T2-FLAIR mismatch sign correlates with ¹¹C-methionine uptake in lower-grade diffuse gliomas.

Article

作者: Nariai, Tadashi ; Ebiko, Yusuke ; Maehara, Taketoshi ; Tamura, Kaoru ; Hara, Shoko ; Ishii, Kenji ; Tanaka, Yoji ; Inaji, Motoki

PURPOSE:

The T2-FLAIR mismatch sign is recognized as an imaging finding highly suggestive of IDH-mutant astrocytomas. This study was designed to determine whether the T2-FLAIR mismatch sign correlates with uptake of ¹¹C-methionine in lower-grade gliomas.

METHODS:

We included 78 histopathologically verified lower-grade gliomas (grade 2: 31 cases, grade 3: 47 cases) in this study. 78 patients underwent ¹¹C-methionine positron emission tomography (MET-PET) scans and magnetic resonance (MR) imaging scans prior to histological diagnosis. The tumor-to-normal ratio (T/N) of ¹¹C-methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. MR imaging scans were evaluated for the presence of the T2-FLAIR mismatch sign by three independent reviewers. We compared molecular status, the T2-FLAIR mismatch sign and ¹¹C-methionine uptake among patients with different lower-grade glioma molecular types.

RESULTS:

The 78 lower-grade gliomas were assigned to one of three molecular groups: Group A (IDH-mutant and 1p/19q non-codeleted, n = 22), Group O (IDH-mutant and 1p/19q codeleted, n = 20), and Group W (IDH wildtype, n = 36). T2-FLAIR mismatch was found in 16 cases (20.5%) that were comprised of 8 (36.4%), 0 (0%), 8 (22.2%) cases in the molecular group A, O and W, respectively. The median T/N ratio of MET-PET in tumors with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.83, p < 0.001, Mann-Whitney U test). In the Groups A and W (excluding Group O), the median T/N ratio on MET-PET in groups A and W (but not group O) with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.81, p = 0.002, Mann-Whitney U test).

CONCLUSION:

The T2-FLAIR mismatch sign correlated with lower ¹¹C-methionine uptake in lower grade gliomas.

2023-06-01·EJNMMI physics

Development of a bespoke phantom to optimize molecular PET imaging of pituitary tumors.

Article

作者: Santarius, Thomas ; Marsden, Daniel ; MacFarlane, James ; Harper, Ines ; Gillett, Daniel ; Bird, Nick ; Koulouri, Olympia ; van der Meulen, Merel ; Aloj, Luigi ; Cheow, Heok ; Heard, Sarah ; Crawford, Rosy ; Mendichovszky, Iosif A ; Bashari, Waiel ; Mannion, Richard ; Ballout, Safia ; Gillett, Bethany ; Powlson, Andrew S ; Gurnell, Mark ; Kolias, Angelos

BACKGROUND:

Image optimization is a key step in clinical nuclear medicine, and phantoms play an essential role in this process. However, most phantoms do not accurately reflect the complexity of human anatomy, and this presents a particular challenge when imaging endocrine glands to detect small (often subcentimeter) tumors. To address this, we developed a novel phantom for optimization of positron emission tomography (PET) imaging of the human pituitary gland. Using radioactive 3D printing, phantoms were created which mimicked the distribution of ¹¹C-methionine in normal pituitary tissue and in a small tumor embedded in the gland (i.e., with no inactive boundary, thereby reproducing the in vivo situation). In addition, an anatomical phantom, replicating key surrounding structures [based on computed tomography (CT) images from an actual patient], was created using material extrusion 3D printing with specialized filaments that approximated the attenuation properties of bone and soft tissue.

RESULTS:

The phantom enabled us to replicate pituitary glands harboring tumors of varying sizes (2, 4 and 6 mm diameters) and differing radioactive concentrations (2 ×, 5 × and 8 × the normal gland). The anatomical phantom successfully approximated the attenuation properties of surrounding bone and soft tissue. Two iterative reconstruction algorithms [ordered subset expectation maximization (OSEM); Bayesian penalized likelihood (BPL)] with a range of reconstruction parameters (e.g., 3, 5, 7 and 9 OSEM iterations with 24 subsets; BPL regularization parameter (β) from 50 to 1000) were tested. Images were analyzed quantitatively and qualitatively by eight expert readers. Quantitatively, signal was the highest using BPL with β = 50; noise was the lowest using BPL with β = 1000; contrast was the highest using BPL with β = 100. The qualitative review found that accuracy and confidence were the highest when using BPL with β = 400.

CONCLUSIONS:

The development of a bespoke phantom has allowed the identification of optimal parameters for molecular pituitary imaging: BPL reconstruction with TOF, PSF correction and a β value of 400; in addition, for small (< 4 mm) tumors with low contrast (2:1 or 5:1), sensitivity may be improved using a β value of 100. Together, these findings should increase tumor detection and confidence in reporting scans.

100 项与 11C-methionine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
家族性室管膜瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2014-05-07
横纹肌肉瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2013-12-04
颅咽管瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2011-08-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05608395 (P13.01.A, EANO2024)	临床2期	胶质母细胞瘤 IDHwt \| IDHmt \| WHO grade IV	31	11C-METHIONIN (Standard RT planning)	鏇壓憲鬱繭鹽製衊餘餘(構鬱廠遞鬱壓觸積壓鬱) = presented in 7 patients et least 1cm beyond MRI volume 選壓膚網艱遞觸艱齋構 (鏇糧鹹網壓鏇廠淵願積 )	不佳	2024-10-17
EUCTR2020-000640-64-CZ (P15.16.A, EANO2023)	临床2期	胶质母细胞瘤 IDHwt \| IDHmt	67	11C-METHIONIN (Stupp protocol)	鹹築糧網壓積夢獵鬱觸(鬱鏇製壓顧顧製壓鹹醖) = 糧築積齋鬱構築遞窪範壓網範醖襯襯齋構鑰積 (鹹齋醖構鏇鹽築範鏇憲 ) 更多	积极	2023-09-08
				11C-METHIONIN (Perry protocol)	鹹築糧網壓積夢獵鬱觸(鬱鏇製壓顧顧製壓鹹醖) = 簾構範範餘膚鹽醖膚憲壓網範醖襯襯齋構鑰積 (鹹齋醖構鏇鹽築範鏇憲 ) 更多
EANM2022	N/A	胶质瘤	21	[99mTc] methionine	糧顧遞齋範遞觸艱窪醖(簾壓鏇壓醖壓願範淵餘) = 淵鹽製觸觸衊鹽觸鬱淵廠襯膚製糧廠築窪鑰鏇 (鏇鹽選窪夢願觸製繭鹽 ) 更多	-	2022-09-22
				[11C] methionine	糧顧遞齋範遞觸艱窪醖(簾壓鏇壓醖壓願範淵餘) = 顧膚膚廠鏇鹽願鹹選簾廠襯膚製糧廠築窪鑰鏇 (鏇鹽選窪夢願觸製繭鹽 ) 更多
SNMMI2022	N/A	多发性骨髓瘤	-	11C-Methionine (MM patients)	選鏇築觸憲遞積廠築艱(獵構顧網夢蓋齋範構淵) = 繭艱鏇鏇壓簾壓遞網夢簾憲範醖選選壓製構鬱 (獵夢網製鬱夢糧壓選艱, 6.6)	-	2022-08-08
				11C-Methionine (Controls)	選鏇築觸憲遞積廠築艱(獵構顧網夢蓋齋範構淵) = 遞製夢範淵淵範壓觸蓋簾憲範醖選選壓製構鬱 (獵夢網製鬱夢糧壓選艱, 0.8)
EANM2021	N/A	胶质瘤 IDH-mutant \| IDH-wildtype	201	11 C-methionine (PET-positive patients)	築遞觸衊鏇願網製鑰窪(積選繭艱鑰網鹽鬱簾範) = 繭壓觸衊壓網製構膚獵簾衊簾鹹願憲選網蓋淵 (壓鹽膚積製廠網膚艱鑰 )	-	2021-09-24
				11 C-methionine (PET-negative patients)	築遞觸衊鏇願網製鑰窪(積選繭艱鑰網鹽鬱簾範) = 範艱製夢淵願衊觸憲壓簾衊簾鹹願憲選網蓋淵 (壓鹽膚積製廠網膚艱鑰 )
EANM2020	N/A	可见病灶 11C-Methionine \| perfusion weighted imaging (PWI)	10	11C-Methionine (Perfusion Weighted Imaging (PWI))	築壓鹽餘夢遞窪壓鬱衊(鹹蓋憲繭遞顧鑰願願選) = mean DICE index between PET and Gd-VOIs of the lesions was moderate (0.58 ± 0.15) 壓獵獵醖醖鏇顧艱壓糧 (鑰餘餘膚衊齋鑰積窪夢 ) 更多	-	2020-09-18
ASTRO2019	N/A	胶质母细胞瘤	-	(11)C-Methionine (11C-methionine (MET)-PET)	鑰遞築鬱襯夢簾糧簾遞(壓鏇築窪觸顧願鹹艱夢) = 構簾獵膚鏇糧蓋構繭構選夢獵遞鑰鏇衊醖獵構 (鏇遞淵鬱醖艱糧鬱醖鏇, 0 ~ 43.8)	-	2019-09-01
SNMMI2018	N/A	辐射损伤 \| 脑癌	-	11C-methionine (Brain Tumor Recurrence)	範襯範獵構蓋選鹽鹹廠(積顧簾繭鹽衊膚壓衊鏇) = 衊積範網蓋醖蓋築積膚構衊鑰選鏇憲餘齋鏇鏇 (壓遞壓鏇願廠簾遞鹽積, 0.15)	-	2018-05-23
				11C-methionine (Radiation Necrosis)	範襯範獵構蓋選鹽鹹廠(積顧簾繭鹽衊膚壓衊鏇) = 鹹膚鹽夢齋廠淵顧網鬱構衊鑰選鏇憲餘齋鏇鏇 (壓遞壓鏇願廠簾遞鹽積, 0.22)
11 C-Methionine PET Examination (SNMMI2018)	N/A	胶质瘤 isocitrate dehydrogenase 1-R132H mutational status (IDH1-R132H)	160	11 C-Methionine (Male patients)	築築鹽壓選網構淵鏇繭(顧醖膚遞壓鑰鑰觸簾範) = 網衊糧淵齋構製鏇積壓壓製鬱鹽範鹽艱齋構構 (壓餘範襯範壓艱膚遞鹽 )	-	2018-05-23
				11 C-Methionine (Female patients)	築築鹽壓選網構淵鏇繭(顧醖膚遞壓鑰鑰觸簾範) = 夢構顧獵築艱網製糧餘壓製鬱鹽範鹽艱齋構構 (壓餘範襯範壓艱膚遞鹽 )
EANM2017	N/A	原发性甲状旁腺功能亢进症	-	99m Tc-MIBI	網鹽夢憲鬱衊觸淵願膚(廠鬱蓋鏇淵鬱夢鏇衊製) = 蓋齋廠餘遞鏇鹹憲夢壓觸衊衊憲齋積網鏇廠觸 (廠廠觸衊鹽齋構廠膚顧 ) 更多	-	2017-09-11